The misery that ensues from recurrent vulvovaginal candidosis (VVC) was eloquently described by Rosalind Hurley! in 1975. In the 15 years since, there has been a considerable amount of work into the aetiology and management of recurrent VVe. This article reviews current knowledge of the causes of recurrent VVC and suggests an approach to managing patients with this complaint.
AETIOLOGY OF VVC AND RECURRENCE
Perhaps the major controversy over the aetiology of VVChas been whether it is an 'infection' of the vagina with a virulent strain of candida with recurrence resulting from reinfection or non-eradications", or whether it is due to an opportunistic overgrowth of a common commensals.
Infection?
The 'infection' concept of VVC was suggested by early studies which showed that vaginal inoculation of candida, in healthy women, caused symptomatic VVCS. The amount of inoculum in these studies, however, was far greater than the probable natural initiating dose. Moreover, the attacks caused were usually self-limiting.
A variety of studies have investigated whether VVC is due to particular virulent strains or species of yeast. These have shown that although most episodes of VVC are due to Candida albicans a substantial minority of cases are due to other species mainly Candida glabrattf>. In symptomatic VVC there is only a slight preponderance of certain phenotypic subtypes of C. albicans 7 ,8 as assessed by the biotyping and resistogram methods of Odds? and Warnock'" although Cassone et al. l1 showed significantly increased proteinase production in isolates from symptomatic compared to asymptomatic carriage.
Sexual transmission as the possible source of the candidal 'infection' has been suggested from concurrent isolation of candida from the vagina and 13 showed a correlation between sexually transmitted diseases, particularly non specific infection, and VVC in patients attending a genitourinary medicine clinic. Conversely Poxmanls, in a study of American college girls, found an association with the frequency of intercourse, but not with high risk behaviour for sexually transmitted diseases. An uncontrolled study has reported carriage of candida in the semen and mouths of partners of women with recurrent VVC and cessation of their recurrent VVC when condoms were used and/or oral sex was avoidedl''.
The rectum is another suggested source of candida. Epidemiological studies have shown a close correlation between anal and rectal candida! carriage with symptomatic disease I 6 ,17, and also a correlation between biotypes of candida from the vagina and rectum18.
Vaginal relapse due to deep-seated candida in vaginal tissues has also been suggested as a cause of recurrences'", Short term recurrences are usually of the same biotype. However the same biotype is found less frequently when the time to recurrence is more than 3 months/:17. The reliability of this long-term conclusion may be doubtful, as recent studies have shown rapid switching of phenotypic characteristics of single genotypes of candida between recurrences-".
Overgrowth?
Support for the alternative concept of VVC as an overgrowth of a normal commensal comes from studies demonstrating vaginal candida carriage rates of 20% or more in asymptomatic women" and those showing a correlation between symptoms and quantitative vaginal counts of candida 2 1,22. This correlation is not, however, particularly close. Sampling error may be one reason, or this may be a reflection of individual variations in susceptibility and organism virulence.
Clinical intervention studies mostly support the concept of VVC as an opportunist overgrowth. Attempts to reduce rectal candida carriage rates with nystatin caused a small reduction in the frequency of recurrences in only one of 3 studies 23 -25 • Similarly, no significant reduction in recurrences has been shown by the concurrent treatment of sexual partners with either local or systemically absorbable antifungals 26-28. In a study comparing a single dose of fluconazole 150mg against c1otrimazole 200 mg for 3 days slightly less clinical recurrences were evident at 6 weeks with fluconazole29. The suggested reason was a reduction in vaginal relapse but other factors may have been involved. Also, in contrast, the use of maintenance ketoconazole for the suppression of recurrent we gave rise to increased recurrences immediately after cessation of treatment compared to a control group-".
Immunity
It would seem that, even if some patients with recurrent we do have an 'infection' with a particularly virulent strain of candida, for most there must be some other change in susceptibility to We.
The most fully investigated area in this regard is the role of cell-mediated immunity. The importance of this is illustrated by the increased prevalence of we in HIV seropositive womerr". Decreased lymphocyte proliferation to candidal antigen has been found in groups of women with recurrent we 32 -34 • More specifically Witkin et al. 35 have shown that many women with recurrent we have a defect of macrophage presentation of candidal antigen to their T lymphocytes which is reversed, in vitro, by prostaglandin inhibitors. Further work showed lymphocyte proliferation to candidal antigen to vary with the menstrual cycle 36 • Mendling and Koldovsky34 also showed significant reductions in T lymphocyte numbers in a study of 18 women with recurrent we compared with 55 controls. In an animal model, candidal antigen has been shown to directly induce suppressor T lymphocytes'".
Although T cell response is important for the prevention of we, activated lymphocytes are unlikely to directly prevent overgrowth of candida. This may be effected by local production of antibodies particularly secretory IgA. Romero-Piffiguer et aI.38 have shown reduced vaginal anti-candidal IgA in women with recurrent We.
Finally, in some patients, increased local and systemic production of anti-candidal IgE39,40 may give rise to allergic symptoms from lower amounts of candida in the vagina than would normally cause problems.
Hormones
Hormonal status is another important factor, with we occurring more commonly at times of oestrogen increase, eg premenstrually and during pregnancy. Although the modem low dose combined oral contraceptive is now thought not to be a predisposing factor4,41 a reduction in recurrences has been shown with the use of depot progesterone'S. These hormonal factors may work not o~y by affecting cell mediated's and local immunity4" but also by increasing vaginal epithelial turnover. This increased turnover produces more intermediate squames in the upper layers of the vaginal epithelium which may bind candida more avidly than superficial squamesw
Normal vaginal flora
The normal vaginal flora has been thought for many years to have an important role in the prevention of we because of the clinical association between antibiotic therapy and an attack of We. This was thought to have been due to the production of inhibitory growth factors or by competitive exclusion of candidal adherence by the vaginal lactobacilli.
The evidence that lactobacilli can inhibit candidal growth is, however, conflicting". Furthermore increased rather than decreased amounts of lactobacilli have been demonstrated in association with symptomatic we 45 • This may indicate that inhibitory growth factors produced by lactobacilli are not important, but does not exclude their role as competitive excluders. There is little work on this, but Sobel et al. 46 history of we and 207 normal controls showed an association between a history of we and fibre intake, total calories and carbohydrates. These studies need to be followed up with prospective controlled studies. Edman et a1. 49 in a study of 49
women showed an association between recurrent we and low zinc. Iron deficiency has now been discounted as an important factorS°.
The trauma of intercourse itself may sometimes be a factor and 'Honeymoon we is a common clinical entity. As already mentioned Poxman'-, in contrast to Thin et al. 13 , showed an association between symptomatic we and intercourse independently to other risk factors. Tight clothing and hot climates have also been said to predispose to we and there are some data from Nigeria to support this51.
MANAGEMENT OF RECURRENT VVC
The approach to the management of severe recurrent we in many ways mirrors that of recurrent herpes genitalis; careful counselling is important and the mainstay of treatment for severe cases is by suppression of symptomatic attacks.
Assessment
It is very important that there should be careful confirmation of the diagnosis'<. There can be little doubt of this in patients with a clear history of recurrent, non-offensive vaginal discharge and vulval irritation associated with rapid, if only temporary, resolution of symptoms with anticandidal therapy. It is, however, better to back this up with mycological proof of heavy growths of candida on at least 2 occasions, and perhaps also negative cultures coinciding with the resolution of symptoms.
The differential diagnosis includes infection with
Trichomonas vaginalis, anaerobic vaginosis and other causes of a recurrent discharge. Initial examination should include screening for causes of a cervicitis, including chlamydia and gonorrhoea, as persistent vaginal discharge due to an infected cervical ectopy is commonly seen in gynaecology clinics 53 . This can be diagnosed by direct examination with confirmation by colposcopy. Other causes of vulval symptoms may also cause confusion and a careful assessment perhaps including vulval colposcopy should be performed. Glycosuria or a random blood sugar should also be checked but these are usually normal.
Suppression of symptoms
Studies have shown that symptoms may usually be suppressed by the use of cyclical or maintenance anticandidal therapy and this remains the cornerstone of treatment.
No direct comparative data between various preparations is available and whether oral treatment offers anything other than patient acceptability is unknown. Many patients will be of childbearing age and since oral systemic preparations are contraindicated in pregnancy it may be better in general to start with intravaginal treatments, which are also cheaper. With local treatment there is a balance to be struck between the frequency of administration (and associated mess and inconvenience) and efficacy. In the study by Balsdon and Tobin 55 , using twice weekly 100mg miconazole pessaries for 3 months followed by once weekly administration for 3 months, none of the women who remained on treatment had symptomatic recurrences. Several studies have used clotrimazole 500 mg single dose pessaries 56 -58 These, in comparison to placebo, have shown significant reductions in symptomatic recurrences when used once monthly post menses's and when used twice monthly (one week before and just after menses)57. Reductions in recurrences only just reached significance (P<0.05) in one of two studies of once monthly administration one week before menses. It is probably best therefore, with intravaginal regimens, to start with single dose treatments, usually one week before an expected period and then a further dose post menses 2 weeks later. If symptoms respond poorly it may be worth trying a different type of local preparation in case this itself is producing local irritation. If response is only partial then more frequent dosing can be attempted or a change made to systemic anticandidals. One interesting finding from these studies, which fits with the concept of symptomatic we being an overgrowth of candida, is that culture of candida from the vagina during treatment did not necessarily equate with a recrudescence of symptoms 55 ,57 . Of the systemically-active antifungals, published studies of sup~ressive regimens are only available for ketoconazole-,30. Studies of fluconazole are underway but there are, as yet, no definitive results'". Sobel, in a placebo-controlled, randomized study, compared ketoconazole 400 mg during menses and 100mg daily maintenance30. Twenty-one women in each group completed 6 months follow-up. The maintenance regimen was found to be superior to the intermittent regimen which in turn was superior to placebo (P<O.OOl, P<O.Ol).
Whatever regimen is chosen treatment should be continued for at least 6 months and then reviewed. In view of the lack of information about the natural history this is admittedly an arbitrary choice. Clearly management must be tailored to the individual case.
/Other areas'
Psychological and psychosexual problems, which are common in these patients, should not be overlooked. Simple, early advice may prevent many problems. It is particularly important for the patient to realize that, even if the symptoms from the we are suppressed, associated vaginismus of other problems may not necessarily resolve immediately. It is also important that the patient should not be given unreal expectations of a permanent or immediate cure.
The question of whether partners should be investigated is often raised by the patient themselves. If recurrences have continued unabated during periods of sexual abstinence this is unnecessary. If there is any doubt a practical approach may be to advise the use of condoms for several months and avoidance of oral sex. If this results in a marked decrease of recurrences, semen cultures should be collected and a concurrent course of systemic anticandidals to the partner can be tried.
Patients will often have read one or more of the self-help guides which abound. The advice from these is variable but is often a cause of anxiety and in desperation some women may obsessively follow some of the unproven suggestions made. Issues commonly raised include the role of diet. Advice on this should perhaps be cautious but, in general, a reduction in carbohydrate intake including artificial sweeteners and the taking of zinc supplements are unlikely to be harmful. It would seem sensible to avoid perfumes and douches. Vaginal yoghurt tampons are frequently advocated but, at least in episodic WC, these do not seem to be effective'". If there is a need for an effectivecontraceptive depot progesterone may be preferable.
THE FUTURE
To effect a permanent cure treatment will need to act either at the level of the immune system or perhaps by biotherapy. Efforts in these directions have, to date, been few although there are some interesting new developments. Hobbs et aI. 32 failed to demonstrate any clinical response to levamisole. Witkin et aI. 35 showed that the specific immune deficit they described may be reversed in vitro with ibuprofen but there has been no confirmation of this or any formal clinical evaluation. Mendling and Koldovsky'< in a small open study of 18 patients found some benefit from thymopentin. Five and three patients, respectively, were cured or improved over a 2 year follow-up period. The majority of those who improved were patients with low initial T cell counts. An orally-administered ribosomal candida vaccine is under investigation and the initial results are promising60. In an initial open study, 20 of 22 patients with severe recurrent we completed 6 months follow-up. In these patients there was a reduction from an average of 3.30 attacks of WC per 6 months, before treatment, to 0.55per 6 months while on treatment. No attacks at all were seen in 8 women on the highest dose of vaccine. Whether these improvements persisted after cessation of treatment was not stated and the results of a placebo controlled randomized trial are awaited. Desensitization may be of help in those patients who are unresponsive to other treatments'". This requires further investigation but, in view of the dangers of desensitization, will probably remain a treatment for use only in a few expert hands in certain highly-selected patients.
